Abstract: It is documented that deficient fucosylation may play an important role in the pathogenesis of cancer. Since the supplementation ofL-fucosecouldrestorefucosylationinbothin vitro and in vivoconditions,ourintentwastoexaminetheeffectofintraperitoneal administration of L-fucose and L-rhamnose (a similar deoxysaccharide) on tumour growth, mitotic activity and metastatic setting ofasolidformofEhrlichcarcinomaaswellasonthesurvivalrateoftumourbearingmice.BothL-fucoseandL-rhamnoseexerted a significant suppressive effect on tumour growth (P<0.05). After 10 days of therapy, the greatest inhibition of tumour growth expressedasapercentageofcontrolswasobservedinL-rhamnoseatadoseof3g/kg/day(by62%)andL-fucoseatadoseof 5g/kg/day(by47%).Moreover,themitoticindexdecreasedwithincreasingdosesofL-fucoseandL-rhamnose.Prolongedsurvivalof tumourbearingmicewasobservedafter14consecutivedaysofdailyadministeringL-rhamnose.Itsoptimaldosewasestimatedto be3.64g/kg/day.L-Fucose,however,displayedonlyaslighteffectonthesurvivalofthemice.OurresultssuggestthatL-fucoseand especiallyL-rhamnosehaveanticancerpotential.Thisstudyisthefirsttodemonstratethetumour-inhibitoryeffectofL-rhamnose.
Introduction
Altered metabolism of a-L-fucose in patients with different types of cancer has been shown to play an important role in the malignant behaviour of tumour cells. These changes include underexpression, overexpression or neoexpression of fucose-containing carbohydrate structures of specific N-glycans, mucin-type O-glycans and glycoproteins of the cell surface as well as elevated serum fucose concentrations [1, 2] . Many of these alterations appear to be associated with tumour progression [3, 4] . As several molecules modified by fucosylation are known mediators of cell signalling, such as sialyl X, sialyl Le x and Le a , or intercellular adhesion (cadherins, integrins and CD44) [5] , the possible consequences are altered differentiation, invasion, metastasis, reduced adhesion to the substratum and uncontrolled growth [6, 7] . For instance, enhanced α-1,6-fucosylation in N-glycans correlates with a higher metastatic potential. The activity of the competent enzyme, α-1,6-fucosyltransferase (α-1,6-fT), is highly elevated in certain tumours [8, 9] . Geng et al. (2004) assume that overexpressed α-1,6-fT may impair the function of E-cadherin by its core fucosylation and thereby inhibit cell-cell adhesion [10] . On the other hand, transfection of α-1,6-fT into the human hepatoma cells Hep3B suppressed intrahepatic metastases to the host liver in vivo [11] . Recently, the same research group has demonstrated that core fucosylation of E-cadherin in α-1,6-fT transfected human colon carcinoma WiDr cells enhanced cell-cell adhesion [12] .
Altered fucosylation of the cell surface was also supposed to contribute to the ability to escape from immune control [13] . In the cytosol of mammalian cells, there are two pathways resulting in the production of GDP-fucose, the fucose donor for fucosylation: the de novo pathway and the salvage pathway. In the de novo pathway, GDP-fucose is provided by synthesis from GDP-mannose, in the salvage pathway by the utilization of L-fucose from extracellular or lysosomal sources. In the de novo pathway, GDP mannose is converted to GDP-fucose by two enzymes, GDP-mannose-4,6-dehydratase (GMD) and 3,5-epimerase-4-reductase [14] . In fact, mutations of the gene for GMD have been described in different human cancer cells. These mutations were found to cause resistance to natural killer cell-mediated tumour surveillance by TNF-related apoptosisinducing ligand (TRAIL) signalling [15] , a pathway which plays an important role in the T-cell mediated killing of oncogenically transformed cells [16] . Since the addition of L-fucose to the medium of GMD-lacking cells can recover fucosylation [17] , providing L-fucose in vivo may under certain circumstances help sensitise cancer cells to the natural immune defence. The effect of intravenously administered L-fucose on the growth of solid rat mammary adenocarcinoma in vivo had already been observed by a research group at the end of the 1960s [18] [19] [20] [21] . Unfortunately, only scant attention was paid to these findings. Later, the potential antimetastatic activity of L-fucose and L-fucose containing oligosaccharides was reported [22] . Thus, the effect of L-fucose administration in cancer disease may be of interest.
On a related note, there can be another candidate, a similar, naturally occurring, non toxic 6-L-deoxyhexose -L-rhamnose (6-deoxy-L-mannose). L-rhamnose is synthesized largely in plants, fungi and prokaryotes but not in animal cells [23] . Interestingly, it can serve as a substrate for the mammalian L-fucose kinase [24] which catalyzes the first step in the salvage pathway for GDP-fucose biosynthesis [14] and it can be incorporated into glycosides in mammals [25, 26] . Hence, L-rhamnose might also influence the fucosylation in tumour cells. Additionally, many lectins expressed by mammalian cells have been shown to be specific for the recognition of L-rhamnose [27] . Their role is still unclear, but it could be fair to assume that interactions between rhamnosides and animal cells might be important in physiological as well as in pathological conditions [28] . Despite the unexplored potential of L-rhamnose, few studies have been devoted to investigating its effect on carbohydrate metabolism in cancer.
In this pilot study, we examined the effect of intraperitoneal (i. p.) administration of L-fucose or L-rhamnose, respectively, on the growth, mitotic activity and metastatic setting of the solid form of Ehrlich carcinoma in immunocompetent mice. We also studied the survival rate of these tumour bearing mice.
Experimental Procedures

Tumour growth in vivo
One hundred and twenty two NMRI female mice weighing 30.0 g (SD=2.18) obtained from BioTest s.r.o. (Konárovice, Czech Republic) were fed a standard diet and water ad libitum. The solid Ehrlich tumour (SET) was purchased from the Research Institute for Pharmacy and Biochemistry, VUFB, Prague, Czech Republic, and then maintained by transplantations in our laboratory. The tumour was inoculated subcutaneously in to 70 animals using 0.2 ml of 1/1 (v/v) homogenate freshly prepared in isotonic glucose solution on day 0. Mice were then divided into 14 groups as follows: saline treated control with SET; six groups of SET bearing animals treated with 1, 3, or 5 g/kg/day L-fucose or L-rhamnose, respectively; six control groups without SET receiving 1, 3, or 5 g/kg/day L-fucose or L-rhamnose, respectively; saline treated control without SET. Each group with tumour inoculums consisted of 10 animals; the groups without tumours contained 8 animals each. L-fucose and L-rhamnose were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA) and were of the highest purity available. Startingon day 1, daily intraperitoneal injections of 20 ml/kg of the solutions of these deoxysugars in 0.9% saline were given to the treated animals for the duration of the experiment. Mice were weighed on the first, second, fourth, seventh and ninth day. On the eleventh day the mice were sacrificed. They were weighed, and their tumours, livers, lungs, hearts, spleens and blood were weighed and checked histologically.
Survival study
The SET (see above) was inoculated into seven groups of seven NMRI female mice (see above for their origin and care; body weight 32.1 g, SD = 3.56) on day 0. From day 1 to day 14 the mice received intraperitoneally 1, 3 or 5 g/kg/day of L-fucose or L-rhamnose, or saline (control), respectively. Their survival was followed.
The care and handling of mice conformed to European Union recommendations on handling experimental animals and was approved by the Ethical Commission of Charles University in the Czech Republic.
where l(t) is the hazard response at time t for the animals that are treated with x g/kg/day of L-fucose of L-rhamnose, l 0 (t) is the hazard function at time t for the control animals; b 1 and b 2 are the coefficients of the second degree polynomials without an absolute term according to Carter et al. [30] and R is the index of relative hazards. The lowest point of the function should correspond to the optimal dose x opt. It was calculated from the first derivative of the function (1), setting x = 0:
Regression coefficients were estimated by NCSS 2007. The statistical significance of the polynomials was estimated using the Fisher-Snedecor distribution.
Results
Effect on the tumour growth
Both L-fucose and L-rhamnose exhibited a significant inhibitory effect on tumour growth. Figure 1 shows the weight of tumours in mice treated with saline, L-fucose or L-rhamnose on day 11. The type of treatment significantly influenced tumour weight (P<0.0001). The greatest tumour growth inhibition was observed in L-rhamnose 3 g/kg/day (by 62%) and L-fucose 5 g/kg/day (by 47%). Surprisingly, the highest dose of L-rhamnose was not so effective (tumour
Histology
Tissues were fixed in formalin for 7 days. Fixed specimens were cut into the tissue blocks, embedded in paraffin and sectioned into transversal and longitudinal 6-7 μm thick slices. Sections were then routinely stained with hematoxylin and eosin and Masson's blue trichrome. Moreover, immunohistochemical detection of proliferating cell nuclear antigen PCNA (dilution 1:20, Clone PC10, Dako, Denmark) was performed. Antigen retrieval was done in a citrate buffer solution (0.291% sodium citrate, 0.05% Tween 20, pH 6.0) using a microwave for 3 × 5 min [29] . The standard ABC detection method was used with DAB. Mayer's Hematoxylin was used as a counterstain. Images were collected using an Olympus BX51 microscope equipped with a DP25 digital camera. Data were analyzed by Image-Pro Plus 5.1 software (Media Cybernetics, USA). The percentage of tumour necrosis as well as the mitotic index were measured. The presence of metastases and the mitotic index were tested in 20 samples from different organ areas (40 visual fields were observed). The mitotic index was counted as a ratio of PCNA positive and PCNA negative nuclei. Cox's proportional hazards model was used to estimate the relationship between the drug treatment level and length of survival [30] . No significant differences were observed in the weight of the organs examined (liver, lungs, spleen, heart) in all groups of non-tumour mice (data not shown). On the other hand, all tumour bearing groups, including the control animals, exhibited higher liver and spleen weights (P<0.05), regardless of the dose of deoxysugar given (data not shown). Comparing changes in body weight of tumour-free animals during treatment with saline, L-fucose or L-rhamnose did not reveal statistically significant differences.
Statistical Analysis
Corresponding to the tumour growth, the tumour bearing mice showed higher weight gains throughout the experiment, but no significant differences among each other, except for the group receiving L-rhamnose 3 g/kg/day (P<0.05), which also displayed the greatest tumour growth inhibition (Figure 2 ). 
Effect on the survival of tumour bearing mice
A) B) C)
mice. The table shows the geometric means of survival and their confidence intervals. The most pronounced prolongation of survival was observed by the L-rhamnose group receiving a dose of 3 g/kg/day (143% of the control). In Figures 3A and  B , values of the index of relative hazards (expressed as lnR) less than zero indicate a lower risk of death or an improved therapeutic outcome. Whereas administration of L-fucose displayed only a slight effect on the survival of treated mice bearing SET ( Figure 3A) , L-rhamnose prolonged their life span markedly ( Figure 3B ). The optimal doses of 3.04 g/kg/day for L-fucose and 3.64 g/kg/day for L-rhamnose were estimated using the equation (3). Figure 4 shows the histological analysis of SET. A significant decrease in the mitotic index was observed in the tumours of all treated groups except for mice receiving L-rhamnose in a dose of 1 g/kg/day ( Figure 5 ).
Histology
Tumours from mice treated with L-rhamnose at a dose of 1 g/kg/day were of a similar morphology to the saline treated control: mitotic activity was almost the same (MI=27%), and necrotic process represented 5% of the tumour area. In general, necrosis accounted for 5-60% of the tumour area and showed no dose dependency. Metastases were found only in the perivascular space of one liver sample (SET + L-fucose 1 g/kg/day - Figure 6 ). All other organs were classified as normal without tumour invasion.
Discussion
In our study we found that the two 6-deoxyhexoses, L-fucose and L-rhamnose, exhibit promising anticancer activity when administered to tumour bearing mice. We observed significantly slower tumour growth and reduced mitotic activity after the administration of the
tested deoxysugars. L-Rhamnose also significantly prolonged the survival of tumour bearing mice.
In view of the fact that the observed effects of L-fucose and L-rhamnose on tumour growth were similar, some parallels in their mechanisms of action can be expected. However, tumours from mice treated with L-rhamnose at a dose of 1 g/kg/day did not display reduced mitotic fraction in spite of their significantly slower growth. This phenomenon can not be explained by a more rapid necrotic process and its cause remains unknown. There is also a discrepancy between the similar impacts of both deoxysugars on tumour growth and the considerably greater effect of L-rhamnose on the survival of tumour bearing mice. It is likely that L-rhamnose might have a more beneficial impact on the glycosylation of the cancer cell surface than added L-fucose, or that it additionally intervenes in the metabolism or signal pathways of cancer cells. In our previous study [31] , however, we found practically no cytostatic or cytotoxic effect of L-rhamnose in concentrations up to 3.29 (5.75) g/L in vitro. Since L-rhamnose in vitro neither induced apoptosis nor inhibited cell proliferation, DNA and protein synthesis as well as the transplantability of cancer cells [31] [32] [33] [34] , we assume that it does not exert any cytotoxic effect by interacting with energy metabolism in the same manner as e.g. 2-D-deoxyglucose. The question of whether L-rhamnose interferes with energy or signal pathways, however, needs to be answered by specifically aimed experiments. Suppressing the rate of rat mammary tumour cell growth in tissue cell cultures [35] or other different mammal cell cultures [36] by L-fucose may be related to contact inhibition. Thus, L-fucose and L-rhamnose are more likely to influence the complex relations of cancer cells within the affected tissues, particularly their contactdependent apoptosis, invasiveness, metastasis and/or the interactions with the immune system.
The effect of the examined L-6-deoxyhexoses to promote anti-cancer immune defence might be a key one. L-fucose was already shown to augment the cytolytic activity of immune system effector cells and the production of cytokines like interleukin 2 and TNF a [37] . The importance of fucosylation for immune surveillance has been recently reported by Moriwaki et al. [15] . Whereas the growth rates of GMD-lacking and GMD-rescued cells in vitro were similar, when transplanted into athymic mice, GMD-rescued cells showed dramatically suppressed tumour growth and metastasis through NK cell-mediated tumour surveillance as well as higher susceptibility to TRAIL-induced apoptosis [15] . TRAIL or agonistic antibodies against death inducing TRAIL receptors are currently being tested as a promising cancer therapy [16] . As several tumour lines are reported to be resistant to TRAIL-mediated therapy [15] , the administration of L-fucose might benefit such immunotherapy. In this respect, the effect of L-rhamnose on GMD-lacking cells should be also examined.
Micrometastatic processes were found only sporadically. Although the employed solid Ehrlich carcinoma is a suitable model for assessing the effect of variable factors on the metastatic setting, the observed interval of 11 days may have been too short.
A great advantage of the potential clinical use of these two naturally occurring L-6-deoxyhexoses is their lack of toxicity even in relatively high doses. In our study, we observed no adverse effects, including no impact on body weight, and no toxicity of the used doses is reported in the literature. The oral administration of L-fucose (up to 5 daily doses of 492 mg per kg body weight) has already been successfully used in humans to treat congenital leukocyte adhesion deficiency caused by deficient fucosylation on the cell surface [38] . The metabolism of the endogenous L-fucose is described in detail elsewhere [14, 28] , even though its elimination in mammals is not sufficiently understood [39] [40] [41] .
L-rhamnose is present in human food and it is also used in clinical practice, in combination with lactulose [42] or, less frequently, with melibiose [43, 44] as a part of the dual-sugar permeability tests of mucosal barriers. When administered intravenously, L-rhamnose is excreted primarily by the kidneys. Its cumulative 24-hour urinary recovery reported in rats and humans was 65% and about 74%, respectively [45, 46] . The biliary elimination in rats is negligible [47] . The rest of the applied dose seems to be, at least partially, reduced to rhamnitol [48] .
The reported effect of single L-6-deoxyhexoses on the behaviour of cancer in vivo seems to be promising for further research. This study is the first to demonstrate the anti-cancer effect of single L-rhamnose. However, considerable research is needed to understand the mechanism responsible. The major issues to be clarified are the effect of administered L-fucose and L-rhamnose on cell surface glycosylation, on tumour cell apoptosis in vivo and on anti-cancer immune defence.
